Міжнародне товариство дитячого та підліткового діабету (ISPAD) Узгоджене керівництво з основних принципів лікування діабету у дітей і підлітків 2009 р.
DOI:
https://doi.org/10.24026/1818-1384.4(33).2010.96373Анотація
продовження, початок див. у No 1(30), 3(32) 2010
Науковий переклад — Н.Б. Зелінська Переклад на українську — О.Я. Гирявенко
Ragnar Hanas, Kim Donaghue, Georgeanna Klingensmith, Peter G.F. Swift – редактори Узгодженого керівництва ISPAD з основних принципів лікування діабету у дітей і підлітків
Посилання
COLMAN PG, STEELE C, COUPER JJ et al. Islet autoimmunity in infants with a Type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia 2000: 43: 203–209. https://doi.org/10.1007/s001250050030
KIMPIMAKI T, KULMALA P, SAVOLA K et al. Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2002: 87: 4572–4579. https://doi.org/10.1210/jc.2002-020018
KNIP M. Natural course of preclinical type 1 diabetes. Horm Res 2002: 57: 6–11. https://doi.org/10.1159/000053305
DIABETES PREVENTION TRIAL-TYPE 1 DIABETES STUDY GROUP. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002: 346: 1685–1691. https://doi.org/10.1056/nejmoa012350
BINGLEY PJ, CHRISTIE MR, BONIFACIO E et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994: 43: 1304–1310. https://doi.org/10.2337/diab.43.11.1304
VERGE CF, GIANANI R, KAWASAKI E et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996: 45: 926–933. https://doi.org/10.2337/diab.45.7.926
AMERICAN DIABETES ASSOCIATION. Prevention of type 1 diabetes mellitus. Diabetes Care 2003: 26: S140. https://doi.org/10.2337/diacare.26.2007.s140
http://www.diabetestrialnet.org. 2006
GINSBERG-FELLNER F, WITT ME, FEDUN B et al. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Rev Infect Dis 1985:7(Suppl. 1): S170–S176. https://doi.org/10.1093/clinids/7.supplement_1.s170
MCINTOSH ED, MENSER MA. A fifty-year follow-up of congenital rubella. Lancet 1992: 340: 414–415. https://doi.org/10.1016/0140-6736(92)91483-o
HYOTY H, HILTUNEN M, KNIP M et al. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 1995: 44: 652–657. https://doi.org/10.2337/diabetes.44.6.652
AKERBLOM HK, VIRTANEN SM, ILONEN J et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 2005: 48: 829–837. https://doi.org/10.1007/s00125-005-1733-3
NORRIS JM, BARRIGA K, KLINGENSMITH G et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003: 290: 1713–1720. https://doi.org/10.1001/jama.290.13.1713
ZIEGLER AG, SCHMID S, HUBER D, HUMMEL M, BONIFACIO E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003: 290: 1721–1728. https://doi.org/10.1001/jama.290.13.1721
FILIPPI C, VON HERRATH M. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell Immunol 2005: 233: 125–132. https://doi.org/10.1016/j.cellimm.2005.04.009
DAHLQUIST G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 2006: 49: 20–24. https://doi.org/10.1007/s00125-005-0076-4
BOBER E, DUNDAR B, BUYUKGEBIZ A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2001: 14: 435–441. https://doi.org/10.1515/jpem.2001.14.4.435
THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998:128: 517–523. https://doi.org/10.7326/0003-4819-128-7-199804010-00001
KESKINEN PK. First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia 2002: 45: 1639–1648. https://doi.org/10.1007/s00125-002-0981-8
AMERICAN DIABETES ASSOCIATION. Type 2 diabetes in children and adolescents. Pediatrics 2000: 105: 671–680. https://doi.org/10.1542/peds.105.3.671
AMERICAN DIABETES ASSOCIATION. Screening for type 2 diabetes. Diabetes Care 2003: 26: S21-S24. https://doi.org/10.2337/diacare.26.2007.s21
LOMBARDO F, VALENZISE M, WASNIEWSKA M et al. Twoyear prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab Clin Exp 2002: 15: 246–251.
DE BEAUFORT CE, HOUTZAGERS CM, BRUINING GJ et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989: 6: 766–771. https://doi.org/10.1111/j.1464-5491.1989.tb01276.x
SHAPIRO AM, LAKEY JR, RYAN EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000: 343: 230–238. https://doi.org/10.1056/nejm200007273430401
RYAN EA, LAKEY JR, PATY BW et al. Successful islet transplantation: continued insulin reserve provides longterm glycemic control. Diabetes 2002: 51: 2148–2157. https://doi.org/10.2337/diabetes.51.7.2148
SHAPIRO AM, RICORDI C, HERING BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006: 355: 1318–1330. https://doi.org/10.1056/nejmoa061267
ODORICO JS, SOLLINGER HW. Technical and immunosuppressive advances in transplantation for insulin-dependent diabetes mellitus. World J Surg 2002: 26: 194–211. https://doi.org/10.1007/s00268-001-0207-0
GALE EA, BINGLEY PJ, EMMETT CL, COLLIER T. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004: 363: 925–931. https://doi.org/10.1016/s0140-6736(04)15786-3
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
